Genmab’s Darzalex royalties now cover the company’s operating costs and in addition to that, the cancer drug continues its expansion to new markets. And according to CEO, Jan van de Winkel, Genmab could potentially raise its guidance this year.
Zealand Pharma has listed on the Nasdaq Global Select Market in addition to its listing in Copenhagen, raising USD 89 in the process. But the move does not mean the biotech company has lost faith in the Danish investor base, says CEO Britt Meelby Jensen.
The US competitor to Lundbeck’s epilepsy drug Sabril is long in coming and this is partly the reason behind the new guidance hike for the Danish company. In the first half year of 2017, Sabril continued to gain market shares in the US.
Denmark’s ALK is ready to go “full steam” in the launch of a promising tablet against house dust mite allergy on the US market as early as this year. The only obstacle is a formal handover of the marketing permit from former partner Merck, which could push the launch into 2018.
Verdens største høreapparatproducent, schweiziske Sonova, præsenterede torsdag sin nye trådløse platform, der kan give en lille fordel i forhold til de danske konkurrenter GN Hearing og William Demant, mener Sydbank-analytiker Morten Imsgaard.